Filing Flows › Vistagen Therapeutics (VTGN) › Q1 FY26
Vistagen Therapeutics (VTGN) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Aug 7, 2025
Vistagen Therapeutics (VTGN) reported revenue of $244K for the first quarter fiscal 2026 (Q1 FY26), +190% from a year earlier.
Vistagen Therapeutics, Q1 FY26: revenue $244K (+190% year over year), net loss $15.1M, operating cash flow −$18.8M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $244K | — | +190% |
| Operating profit | −$15.8M | — | — |
| Net earnings | −$15.1M | — | — |
| Operating cash flow | −$18.8M | — | — |
What changed
Revenue was $244K in Q1 FY26, up 190% year over year.
Operating costs exceeded revenue by $15.8M, an operating margin of -6477.0%. Total costs grew 31% against revenue growth of 190%. The fastest-growing cost line was Research & development (+53%). The quarter ended with a net loss of $15.1M.
Operating cash flow was −$18.8M. Non-cash charges added back $40K of depreciation and amortization and $916K of share-based compensation. Working capital and other items used $4.7M. Capital expenditures of $65K exceeded it, leaving free cash flow of −$18.9M.
Questions
What was Vistagen Therapeutics' revenue in the first quarter fiscal 2026?
Vistagen Therapeutics (VTGN) reported revenue of $244K for the first quarter fiscal 2026 (Q1 FY26), +190% from a year earlier.